Ophthotech Reports First Quarter 2014 Financial Results and Provides Business …
Business Wire (press release) Ophthotech announced its strategy to expand its Fovista anti-PDGF therapy program beyond the pivotal Phase 3 clinical trials in wet AMD and to advance its Zimura™ program in both dry and wet AMD. Zimura™ is an inhibitor of complement factor C5. |
Source: Wet Macular Degeneration News From Google News